Aprepitant for gefitinib-induced refractory pruritus in Chinese malignancy population

Targeted therapy is an important anti-cancer therapy in non-small cell lung cancer (NSCLC). Pruritus are the common side-effect with gefitinib, an anti-EGFR antibody and tyrosine-kinase inhibitor. We reported case reports to confirm the effects of aprepitant, a neurokinin receptor to management of r...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ann Transl Med
Päätekijät: Qin, Haifeng, Wang, Fang, Wang, Ke, Liu, Hui, Guo, Rui, Zeng, Zhen, Pan, Xin, Fu, Xiaofeng, Zhang, Ting, Gao, Hongjun
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AME Publishing Company 2019
Aiheet:
Case Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6389580/
https://ncbi.nlm.nih.gov/pubmed/30906758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.01.02
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia